Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(5S,6S)-6-[(R)acetooxyeth-2-yl]-penem-3-carboxylatepropane is a synthetic penem derivative. Penems are a subclass of beta-lactam antibiotics structurally related to carbapenems and penicillins. They act by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), leading to bactericidal activity against susceptible bacteria. This compound features a penem core with specific stereochemistry at positions 5 and 6 and an acetooxyethyl side chain at position 6, as well as a carboxylic acid group at position 3. The detailed pharmacological properties, clinical indications, or commercial development status for this specific molecule are not available in the provided sources; however, it is structurally consistent with experimental or investigational antibacterial agents within the penem class[7][3][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (5S,6S)-6-[(R)acetooxyeth-2-yl]-penem-3-carboxylatepropane.